Literature DB >> 11264175

BCR-ABL down-regulates the DNA repair protein DNA-PKcs.

E Deutsch1, A Dugray, B AbdulKarim, E Marangoni, L Maggiorella, S Vaganay, R M'Kacher, S D Rasy, F Eschwege, W Vainchenker, A G Turhan, J Bourhis.   

Abstract

This study demonstrates in both stable and inducible BCR-ABL-expressing hematopoietic cells a down-regulation of the major mammalian DNA repair protein DNA-PKcs by BCR-ABL. Similar results were found in BCR-ABL CD34(+) cells from patients with chronic myelogenous leukemia (CML). DNA-PKcs down-regulation is a proteasome-dependent degradation that requires tyrosine kinase activity and is associated with a marked DNA repair deficiency along with increased sensitivity to ionizing radiation. The conjunction of a major DNA repair deficiency and a resistance to apoptosis, both induced by BCR-ABL, provides a new mechanism to explain how secondary genetic alterations can accumulate in CML, eventually leading to blast crisis. The down-regulation of DNA-PKcs was reversible in CD34(+) CML cells suggesting that this approach might offer a novel and powerful therapeutic strategy in this disease, especially to delay the blast crisis. (Blood. 2001;97:2084-2090)

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11264175     DOI: 10.1182/blood.v97.7.2084

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  40 in total

1.  Genomic instability in chronic myeloid leukemia: targets for therapy?

Authors:  N Muvarak; P Nagaria; F V Rassool
Journal:  Curr Hematol Malig Rep       Date:  2012-06       Impact factor: 3.952

2.  BCR/ABL promotes accumulation of chromosomal aberrations induced by oxidative and genotoxic stress.

Authors:  M Koptyra; K Cramer; A Slupianek; C Richardson; T Skorski
Journal:  Leukemia       Date:  2008-04-10       Impact factor: 11.528

3.  BCR/ABL downregulates DNA-PK(CS)-dependent and upregulates backup non-homologous end joining in leukemic cells.

Authors:  Tomasz Poplawski; Janusz Blasiak
Journal:  Mol Biol Rep       Date:  2009-08-21       Impact factor: 2.316

4.  BCR/ABL modifies the kinetics and fidelity of DNA double-strand breaks repair in hematopoietic cells.

Authors:  Artur Slupianek; Michal O Nowicki; Mateusz Koptyra; Tomasz Skorski
Journal:  DNA Repair (Amst)       Date:  2005-11-16

Review 5.  BCR-ABL: a multi-faceted promoter of DNA mutation in chronic myelogeneous leukemia.

Authors:  B A Burke; M Carroll
Journal:  Leukemia       Date:  2010-05-06       Impact factor: 11.528

6.  hnRNP A1 nucleocytoplasmic shuttling activity is required for normal myelopoiesis and BCR/ABL leukemogenesis.

Authors:  Angela Iervolino; Giorgia Santilli; Rossana Trotta; Clara Guerzoni; Vincenzo Cesi; Anna Bergamaschi; Carlo Gambacorti-Passerini; Bruno Calabretta; Danilo Perrotti
Journal:  Mol Cell Biol       Date:  2002-04       Impact factor: 4.272

Review 7.  Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia.

Authors:  Elias J Jabbour; Timothy P Hughes; Jorge E Cortés; Hagop M Kantarjian; Andreas Hochhaus
Journal:  Leuk Lymphoma       Date:  2013-11-12

8.  BCR/ABL stimulates WRN to promote survival and genomic instability.

Authors:  Artur Slupianek; Tomasz Poplawski; Stanislaw K Jozwiakowski; Kimberly Cramer; Dariusz Pytel; Ewelina Stoczynska; Michal O Nowicki; Janusz Blasiak; Tomasz Skorski
Journal:  Cancer Res       Date:  2010-12-01       Impact factor: 12.701

9.  Loss of DNA-dependent protein kinase catalytic subunit (DNA-PKcs) expression in gastric cancers.

Authors:  Hye Seung Lee; Han-Kwang Yang; Woo Ho Kim; Gheeyoung Choe
Journal:  Cancer Res Treat       Date:  2005-04-30       Impact factor: 4.679

10.  BCR-ABL promotes the frequency of mutagenic single-strand annealing DNA repair.

Authors:  Margret S Fernandes; Mamatha M Reddy; Jeffrey R Gonneville; Scott C DeRoo; Klaus Podar; James D Griffin; David M Weinstock; Martin Sattler
Journal:  Blood       Date:  2009-07-01       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.